// STATE LEGISLATION TRACKER

Pennsylvania SB 1169: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Pennsylvania
Bill: SB 1169
Filed: 2024-05-16
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Pennsylvania SB1169 appears focused on drug overdose medication under the state Controlled Substance, Drug, Device and Cosmetic Act, not peptide access or prescribing. Based on the available title/status, it does not appear to change compounded peptides, off-label prescribing, telehealth, NP/naturopath scope, 503A/503B rules, or PDMP duties.

Key Points

No clear change to compounded peptide access
No visible impact on off-label peptide prescribing
No telehealth or clinician-scope change is apparent
No 503A or 503B compounding change is indicated
Controlled-substance focus appears tied to overdose medication

What to Watch For

Note If reintroduced, check whether the text adds pharmacy, prescribing, or dispensing rules beyond overdose medication.

Note Because it amends the drug law, confirm future versions do not add controlled-substance reporting duties.

Note Current available info suggests no peptide-specific access issue.

Where the Bill Stands

The 2023-2024 bill was introduced on May 16, 2024, referred to Senate Health and Human Services, and died in committee.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws